The leading business intelligence provider GBI Research has released its latest research report, entitled “Travel Vaccines Market to 2019 – Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth”. The report provides insights into the vaccines in the Travel Vaccines market including market forecasts up to 2019. It provides an in-depth analysis of the travel vaccines, as well as insights into the Travel Vaccines R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global Travel Vaccines market.  The report analyzes the market ...

The world market for HCV drugs represents an area of potential opportunities in developed as well as developing countries. Because of the technological advancements and effectiveness, many big market players are focusing on development of innovative drugs for HCV. Major companies are forming coalitions and agreements to develop effective treatment on hepatitis C virus. In future, the growth of HCV market is expected to come from emerging markets of Asia Pacific, Middle East, and Latin America as these regions are likely to register maximum number of HCV incidences due to increasing HCV drug addicts.  Hepatitis C virus (HCV) spreads through the blood of infected person by the use of shared needles or equipments used to inject dr...

EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022SummaryHepatitis C is a largely asymptomatic liver disease caused by the hepatitis C virus (HCV). HCV is an escalating public health problem and burdens an estimated 3% of the worlds population (Trinks et al., 2012). Unlike other acute viral infections that have a rapid onset, HCV infections often persist for decades (CDC, 2013; Tan, 2006).According to the World Health Organization (WHO), approximately 150 million individuals worldwide have been infected with HCV and about 350,000 deaths occur due to HCV-related liver diseases each year (WHO, 2012). HCV transmission in the US is mainly through direct percutaneous exposure to infected blood. HCV in Europe is mainly associ...

Hepatitis Pipeline Review, H1 2013 Summary Global Markets Directs, 'Hepatitis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis. Hepatitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/unive...

Hepatitis C Pipeline Review, H1 2013 Summary Global Markets Directs, 'Hepatitis C Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. Hepatitis C Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from com...

Non-Alcoholic Steatohepatitis Pipeline Review, H1 2013 Summary Global Markets Directs, 'Non-Alcoholic Steatohepatitis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis. Non-Alcoholic Steatohepatitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/Uni...

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2013" provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining t...

2013 Deep Research Report on China Hepatitis B Vaccine Industry was professional and depth research report on China Hepatitis B Vaccine industry.  This report has firstly introduced Hepatitis B Vaccine definition classification industry chain etc related information. Then introduced Hepatitis B Vaccine manufacturing technology and product specifications, And then summary statistics China major Hepatitis B Vaccine manufacturers 2009-2013 Hepatitis B Vaccine capacity production supply demand shortage and Hepatitis B Vaccine selling price cost gross margin and production value, and also introduced China 8 manufacturers company basic information, 2009-2013 Hepatitis B Vaccine capacity production price cost gross margin production v...

Hepatitis D Pipeline Review, H2 2012 Global Markets Directs, 'Hepatitis D Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis D, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis D. Hepatitis D Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global ...

Hepatitis B Pipeline Review, H2 2012 Summary Global Markets Directs, 'Hepatitis B Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis B, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis B. Hepatitis B Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from com...

Steatohepatitis Pipeline Review, H2 2012 Global Markets Directs, 'Steatohepatitis Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Steatohepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Steatohepatitis. Steatohepatitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press release...

Hepatitis C Therapeutics Market to 2018 Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy GBI Research, the leading business intelligence provider, has released its latest research Hepatitis C Therapeutics Market to 2018 Expected Launch of GS-7977 in 2015 will Pave the Way for an Oral Interferon-free Combination Therapy, which provides insights into the global hepatitis C therapeutics market up to 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts. The report examines the global hepatitis C treatment usage patterns, and the geographical di...

TechNavio's analysts forecast the Global Hepatitis Drugs market to grow at a CAGR of 12.42 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increase in demand for hepatitis drugs in developing countries. The Global Hepatitis Drugs market has also been witnessing an increase in the number of mergers and acquisitions. However, the shortage of hepatitis drugs to meet market demand could pose a challenge to the growth of this market. TechNavio's report, the Global Hepatitis Drugs Market 2011-2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hepatitis Drugs market landscape and its growth p...

According to the National Serum Epidemiological Survey of Hepatitis B and the Related Diseases, hepatitis B surface antigen carrier rate of 1 to 59 years old group nationwide is 7.18%. Calculated at this data, there are still about 93 million hepatitis B surface antigen carriers in China. In May 2012, (24 Oclock of May 1st to 24 Oclock of May 31st, 2012), there were 113,147 reported morbidity cases and 56 deaths all over China.Over the years, China has promulgated a series of policies on inoculation of hepatitis B vaccination. However, relative to the high carrier rate of hepatitis B patients in China, the supporting power of the national policies is not enough.The above data shows that there are still many problems in the implementation of hepatitis B vaccine po...

Hepatitis C Pipeline Review, H2 2012 Global Markets Directs, 'Hepatitis C Pipeline Review, H2 2012', provides an overview of the Hepatitis C therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis C. 'Hepatitis C Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by G...

Hepatitis Pipeline Review, H2 2012 Global Markets Directs, 'Hepatitis Pipeline Review, H2 2012', provides an overview of the Hepatitis therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis. 'Hepatitis Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Market...

NonAlcoholic Steatohepatitis Pipeline Review, H2 2012 Global Markets Directs, 'Non-Alcoholic Steatohepatitis Pipeline Review, H2 2012', provides an overview of the Non-Alcoholic Steatohepatitis therapeutic pipeline. This report provides information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis. 'Non-Alcoholic Steatohepatitis Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and feature...

GlobalData, the industry analysis specialist, has released its new report, Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Hepatitis A Preventive Vaccines market. The report identifies the key trends shaping and driving the global Hepatitis A Preventive Vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hepatitis A Preventive Vaccines sector. This report is built using data and information sourced from proprietary databases, p...

GlobalData's clinical trial report, Hepatitis A Global Clinical Trials Review, H1, 2012" provides data on the Hepatitis A clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis A. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis A. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

TechNavios analysts forecast the Global Hepatitis C Drugs market to grow at a CAGR of 28 percent over the period 20112015. One of the key factors contributing to this market growth is the increasing prevalence of hepatitis C infection. The Global Hepatitis C Drugs market has also been witnessing the shift of treatments from multiple drug therapy to single drug therapy. However, the virus developing resistance to the drugs could pose a challenge to the growth of this market. TechNavios report, the Global Hepatitis C Drugs Market 20112015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hepatitis C Drugs market landscape and its g...

GlobalData's clinical trial report, Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2012" provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. This report is built using data and information sourced from proprietary databases, pri...

China's demand for hepatitis drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2001, 2006 and 2011) and long-term forecasts through 2016 and 2021 are presented. Major producers in China are profiled.

GlobalData, the industry analysis specialist, has released its new report, Hepatitis B Therapeutics Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global hepatitis B therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hepatitis B therapeutics market. This report is built using data and information sourced from proprietary databases, primary...

Hepatitis C virus drug market is experiencing a dramatic near-term growth, by crossing US$ 6 Billion in 2011 and is expected to be more than double of its current figure by 2015. This robust growth will be driven primarily by the launch of novel premium-priced agents that will increase the size of the drug-treated population, mainly as a result of the re-treatment of prior non-responder patients. ...

GBI Research’s new report, “Hepatitis Market to 2017 - Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market”, provides in-depth analysis of the unmet need, drivers and barriers impacting the global hepatitis market. The report analyzes the hepatitis markets in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that have shaped the global markets.

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players. This Pipeline Selector report covers Hepatitis B Vaccine Hepatitis B Vaccine indications: Vaccine against Hepatitis B Hepatitis B Vaccine innovator: GlaxoSmithKline (Engerix B, HBvaxPro); Merck (H-B-Vax II) Examples of information found in this online report include: Includes key patent pu...

Eliminate unnecessary risk with the industry benchmark in comprehensive patent information. Pipeline Developer is a regularly updated, professional patent search performed by our expert team, which not only identifies relevant patents, but delivers categorisation and interpretation, all delivered by a convenient online interface.  This Pipeline Developer report covers Hepatitis B Vaccine Hepatitis B Vaccine indications: Vaccine against Hepatitis B Hepatitis B Vaccine innovator: GlaxoSmithKline (Engerix B, HBvaxPro); Merck (H-B-Vax II) Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.&nbs...

GlobalData, the industry analysis specialist, has released its new report, Nonalcoholic Steatohepatitis (NASH) Therapeutics Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Nonalcoholic Steatohepatitis (NASH) Therapeutics market. The report identifies the key trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Nonalcoholic Steatohepatitis (NASH) Therapeutics sector. This report is...

Targeted Therapy of Hepatitis C Product description The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV RNA up to ...

d) and chronic (long-lasting) forms of hepatitis C. The incidence rates of HCV vary noticeably, registering the highest rate in the North America. In the past few years, the cases of HCV have increased tremendously in the US, European, Asian and African regions. Comprising of two segments - diagnostic and treatment, the HCV market is driven by various factors like growing world population, obesity, increasing number of HCV incidences globally and rise in number of HCV positive drug addicts. The global market for HCV drugs represents an area of potential opportunity in both developed and developing countries. Due to the effectiveness and advancements in technologies, large number of companies are focused on developing innovative HCV drugs. Further, the companies...

GlobalData's clinical trial report, Hepatitis B Global Clinical Trials Review, Q2, 2011" provides data on the Hepatitis B clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis B. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis B. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry ex...

GlobalData's clinical trial report, Hepatitis C Global Clinical Trials Review, Q2, 2011" provides data on the Hepatitis C clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis C. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis C. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry ex...

GlobalData's clinical trial report, Hepatitis A Global Clinical Trials Review, Q2, 2011" provides data on the Hepatitis A clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatitis A. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatitis A. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry ex...

GlobalData's clinical trial report, Non-Alcoholic Steatohepatitis Global Clinical Trials Review, Q1, 2011" provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic Steatohepatitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Alcoholic Steatohepatitis. This report is built using data and information sourced from proprietary databases, primary and secondary ...

GlobalData, the industry analysis specialist, has released its new report, Hepatitis A Preventive Vaccines Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Hepatitis A Preventive Vaccines market. The report identifies the key trends shaping and driving the global Hepatitis A Preventive Vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hepatitis A Preventive Vaccines sector. This report is built using data and information sourced from proprietary databases...

GBI Research has released its latest research Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets, which essentially provides insights into diabetes therapeutics sales and price forecasts until 2016. The report also examines the global diabetes therapies treatment usage patterns. The report covers the key geographies of the US, the top five countries in the European region and Japan. Insights into the diabetes research and development pipeline and the potential future blockbusters by 2016 are included. The report provides an in-depth analysis of HIV, Hepatitis, Herpes and Influenza therapeutic indications, and includes market forecasts and treatment usage patterns for these two therapeutic indications. The rep...

GlobalData, the industry analysis specialist, has released its new report, “Non-alcoholic Steatohepatitis (NASH) - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global NASH market. The report identifies the key trends shaping and driving the global NASH market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global NASH sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house a...

GlobalData, the industry analysis specialist, has released its new report, Hepatitis B Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global Hepatitis B therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Hepatitis B sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and ...

GBI Research’s pharmaceuticals report, “Hepatitis Therapeutics Market to 2016 - Strong Hepatitis-C Pipeline and Cost Effective Treatments will Drive the Global Hepatitis Market”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global hepatitis therapeutics market. The report analyzes the markets for hepatitis therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements...

GlobalData, the industry analysis specialist, has released its new report, Hepatitis B Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Hepatitis B therapeutics market. The report identifies the key trends shaping and driving the global Hepatitis B therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Hepatitis B sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and ...

GlobalData, the industry analysis specialist, has released a new report, Hepatitis C (HCV) Pipeline Assessment and Market Forecasts to 2016. The report is an essential source of information and analysis on the global HCV market. The report identifies the key trends shaping and driving the global HCV market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to cause significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global hepatitis C sector. GlobalDatas analysis suggests that the global HCV market was worth $4.4 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.8% for the ne...

China's demand for Hepatitis Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (1998, 2003 and 2008) and long-term forecasts throught 2013 and 2018 are presented. Major producers in China are profiled.